Back to School: How biopharma can reboot drug development. Access exclusive analysis here

PTC preclinical data

Researchers at the University of Dundee published preclinical data in PLoS Biology questioning the mechanism of action of PTC's ataluren, which is in Phase III testing to treat nonsense mutation genetic disorders. PTC has described ataluren

Read the full 366 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers